While rituximab has theoretical benefits in all CD20+ malignancies, it is best studied in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, including follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL) [50]. This evidence concerns the gene MS4A1 and diffuse large B-cell lymphoma.